Fabry Disease Race: Former CDER Official Siegel Interprets Committee Votes
During a Jan. 15 conference call sponsored by the Schwab Washington Research Group, former Office of Therapeutics Review & Research Director Jay Siegel, MD, gave his interpretation of the outcome of the advisory committee reviews of the two pending Fabry disease therapies, Genzyme's Fabrazyme and TKT's Replagal. Here are his comments, as transcribed by "The Pink Sheet." Coverage of the committee meetings can be found on pp. 12-16.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth